Genomic landscape of adenoid cystic carcinoma of the breast

Journal of Pathology

Volumn 237, Issue 2, 2015, Pages 179-189

  Martelotto, Luciano G ^a   De Filippo, Maria R ^a   Ng, Charlotte K ^a   Natrajan, Rachael ^b   Fuhrmann, Laetitia ^c   Cyrta, Joanna ^c   Piscuoglio, Salvatore ^a   Wen, Huei Chi ^a   Lim, Raymond S ^a   Shen, Ronglai ^a   Schultheis, Anne M ^a   Wen, Y Hannah ^a   Edelweiss, Marcia ^a   Mariani, Odette ^c   Stenman, Göran ^d   Chan, Timothy A ^a   Colombo, Pierre Emmanuel ^e   Norton, Larry ^a   Vincent Salomon, Anne ^c   Reis Filho, Jorge S ^a   Weigelt, Britta ^a   more..

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^c INSTITUT CURIE   (France)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Department of Surgical Oncology Montpellier Cancer Institute (ICM)   (France)

Author keywords

adenoid cystic carcinoma; genomics; massively parallel sequencing; MYB NFIB; triple negative breast cancer

Indexed keywords

B RAF KINASE; BRCA1 PROTEIN; BRCA2 PROTEIN; FBXW7 PROTEIN; FIBROBLAST GROWTH FACTOR RECEPTOR 2; MAMMALIAN TARGET OF RAPAMYCIN; MESSENGER RNA; PROTEIN; PROTEIN MYB; PROTEIN P53; RNA; SF3B1 PROTEIN; SMARCA5 PROTEIN; TALIN; TALIN 2; UNCLASSIFIED DRUG; UVOMORULIN; MYB-NFIB FUSION PROTEIN, HUMAN; ONCOPROTEIN; TUMOR MARKER;

ADENOID CYSTIC CARCINOMA; ALTERNATIVE RNA SPLICING; AMPLICON; ARTICLE; BASAL LIKE BREAST CANCER; BREAST ADENOID CYSTIC CARCINOMA; BREAST CARCINOMA; CANCER GENETICS; CELL ADHESION; CELL PROLIFERATION; CLINICAL ARTICLE; EXOME; EXON; FLUORESCENCE IN SITU HYBRIDIZATION; FRAMESHIFT MUTATION; FUSION GENE; GENE DOSAGE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE MUTATION; GENE REARRANGEMENT; GENE SEQUENCE; GENETIC HETEROGENEITY; GENOMICS; HUMAN; HUMAN CELL; HUMAN TISSUE; NONSENSE MUTATION; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SALIVARY GLAND CARCINOMA; SIGNAL TRANSDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; SOMATIC MUTATION; TRIPLE NEGATIVE BREAST CANCER; TUMOR GENE; UBIQUITINATION; CHEMISTRY; COPY NUMBER VARIATION; DNA MUTATIONAL ANALYSIS; FEMALE; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; MUTATION; ONCOGENE MYB; PATHOLOGY; PHENOTYPE; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION;

BIOMARKERS, TUMOR; CARCINOMA, ADENOID CYSTIC; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; FEMALE; GENE DOSAGE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE FREQUENCY; GENES, MYB; GENETIC PREDISPOSITION TO DISEASE; GENOMICS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; MUTATION; ONCOGENE PROTEINS, FUSION; PHENOTYPE; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TRIPLE NEGATIVE BREAST NEOPLASMS;

EID: 84940842655     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4573     Document Type: Article

References (51)

1. Marchio C, Weigelt B, Reis-Filho JS,. Adenoid cystic carcinomas of the breast and salivary glands (or 'The strange case of Dr Jekyll and Mr Hyde' of exocrine gland carcinomas). J Clin Pathol 2010; 63: 220-228.
2. Weigelt B, Horlings HM, Kreike B, et al., Refinement of breast cancer classification by molecular characterization of histological special types. J Pathol 2008; 216: 141-150.
3. Lakhani SR, Ellis IO, Schnitt SJ, et al. (eds). WHO Classification of Tumours of the Breast. IARC: Lyon, 2012.
4. Weigelt B, Reis-Filho JS,. Histological and molecular types of breast cancer: is there a unifying taxonomy? Nat Rev Clin Oncol 2009; 6: 718-730.
5. Foulkes WD, Smith IE, Reis-Filho JS,. Triple-negative breast cancer. N Engl J Med 2010; 363: 1938-1948.
6. Yerushalmi R, Hayes MM, Gelmon KA,. Breast carcinoma-rare types: review of the literature. Ann Oncol 2009; 20: 1763-1770.
7. Papaspyrou G, Hoch S, Rinaldo A, et al., Chemotherapy and targeted therapy in adenoid cystic carcinoma of the head and neck: a review. Head Neck 2011; 33: 905-911.
8. Persson M, Andren Y, Mark J, et al., Recurrent fusion of MYB and NFIB transcription factor genes in carcinomas of the breast and head and neck. Proc Natl Acad Sci USA 2009; 106: 18740-18744.
9. Brill LB II, Kanner WA, Fehr A, et al., Analysis of MYB expression and MYB-NFIB gene fusions in adenoid cystic carcinoma and other salivary neoplasms. Mod Pathol 2011; 24: 1169-1176.
10. West RB, Kong C, Clarke N, et al., MYB expression and translocation in adenoid cystic carcinomas and other salivary gland tumors with clinicopathologic correlation. Am J Surg Pathol 2011; 35: 92-99.
11. Mitani Y, Li J, Rao PH, et al., Comprehensive analysis of the MYB-NFIB gene fusion in salivary adenoid cystic carcinoma: incidence, variability, and clinicopathologic significance. Clin Cancer Res 2010; 16: 4722-4731.
12. Ho AS, Kannan K, Roy DM, et al., The mutational landscape of adenoid cystic carcinoma. Nat Genet 2013; 45: 791-798.
13. Stephens PJ, Davies HR, Mitani Y, et al., Whole exome sequencing of adenoid cystic carcinoma. J Clin Invest 2013; 123: 2965-2968.
14. Wetterskog D, Lopez-Garcia MA, Lambros MB, et al., Adenoid cystic carcinomas constitute a genomically distinct subgroup of triple-negative and basal-like breast cancers. J Pathol 2012; 226: 84-96.
15. Wetterskog D, Wilkerson PM, Rodrigues DN, et al., Mutation profiling of adenoid cystic carcinomas from multiple anatomical sites identifies mutations in the RAS pathway, but no KIT mutations. Histopathology 2013; 62: 543-550.
16. D'Alfonso TM, Mosquera JM, MacDonald TY, et al., MYB-NFIB gene fusion in adenoid cystic carcinoma of the breast with special focus paid to the solid variant with basaloid features. Hum Pathol 2014; 45: 2270-2280.
17. Persson M, Andren Y, Moskaluk CA, et al., Clinically significant copy number alterations and complex rearrangements of MYB and NFIB in head and neck adenoid cystic carcinoma. Genes Chromosomes Cancer 2012; 51: 805-817.
18. Shah SP, Roth A, Goya R, et al., The clonal and mutational evolution spectrum of primary triple-negative breast cancers. Nature 2012; 486: 395-399.
19. The Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature 2012; 490: 61-70.
20. Horlings HM, Weigelt B, Anderson EM, et al., Genomic profiling of histological special types of breast cancer. Breast Cancer Res Treat 2013; 142: 257-269.
21. Elston CW, Ellis IO,. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 1991; 19: 403-410.
22. Piscuoglio S, Ng CK, Martelotto LG, et al., Integrative genomic and transcriptomic characterization of papillary carcinomas of the breast. Mol Oncol 2014; 8: 1588-1602.
23. Hammond ME, Hayes DF, Dowsett M, et al., American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 2010; 28: 2784-2795.
24. Wolff AC, Hammond ME, Hicks DG, et al., Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 2013; 31: 3997-4013.
25. Fusco N, Colombo PE, Martelotto LG, et al., Resolving quandaries: basaloid adenoid cystic carcinoma or breast cylindroma? The role of massively parallel sequencing. Histopathology 2015; doi: 10.1111/his.12735. Epub ahead of print.
26. Fehr A, Kovacs A, Loning T, et al., The MYB-NFIB gene fusion-a novel genetic link between adenoid cystic carcinoma and dermal cylindroma. J Pathol 2011; 224: 322-327.
27. Weinreb I, Piscuoglio S, Martelotto LG, et al., Hotspot activating PRKD1 somatic mutations in polymorphous low-grade adenocarcinomas of the salivary glands. Nat Genet 2014; 46: 1166-1169.
28. Li H, Durbin R,. Fast and accurate long-read alignment with Burrows-Wheeler transform. Bioinformatics 2010; 26: 589-595.
29. McKenna A, Hanna M, Banks E, et al., The Genome Analysis Toolkit: a MapReduce framework for analyzing next-generation DNA sequencing data. Genome Res 2010; 20: 1297-1303.
30. Cibulskis K, Lawrence MS, Carter SL, et al., Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol 2013; 31: 213-219.
31. Koboldt DC, Zhang Q, Larson DE, et al., VarScan 2: somatic mutation and copy number alteration discovery in cancer by exome sequencing. Genome Res 2012; 22: 568-576.
32. Saunders CT, Wong WS, Swamy S, et al., Strelka: accurate somatic small-variant calling from sequenced tumor-normal sample pairs. Bioinformatics 2012; 28: 1811-1817.
33. Narzisi G, O'Rawe JA, Iossifov I, et al., Accurate de novo and transmitted indel detection in exome-capture data using microassembly. Nat Methods 2014; 11: 1033-1036.
34. Thorvaldsdottir H, Robinson JT, Mesirov JP,. Integrative Genomics Viewer (IGV): high-performance genomics data visualization and exploration. Brief Bioinform 2013; 14: 178-192.
35. Schwarz JM, Rodelsperger C, Schuelke M, et al., MutationTaster evaluates disease-causing potential of sequence alterations. Nat Methods 2010; 7: 575-576.
36. Carter H, Chen S, Isik L, et al., Cancer-specific high-throughput annotation of somatic mutations: computational prediction of driver missense mutations. Cancer Res 2009; 69: 6660-6667.
37. Martelotto LG, Ng C, De Filippo MR, et al., Benchmarking mutation effect prediction algorithms using functionally validated cancer-related missense mutations. Genome Biol 2014; 15: 484.
38. Kamburov A, Stelzl U, Lehrach H, et al., The ConsensusPathDB interaction database: 2013 update. Nucleic Acids Res 2013; 41: D793-800.
39. Mermel CH, Schumacher SE, Hill B, et al., GISTIC2.0 facilitates sensitive and confident localization of the targets of focal somatic copy-number alteration in human cancers. Genome Biol 2011; 12: R41.
40. Carter SL, Cibulskis K, Helman E, et al., Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol 2012; 30: 413-421.
41. Lawrence MS, Stojanov P, Polak P, et al., Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature 2013; 499: 214-218.
42. Futreal PA, Coin L, Marshall M, et al., A census of human cancer genes. Nat Rev Cancer 2004; 4: 177-183.
43. Kandoth C, McLellan MD, Vandin F, et al., Mutational landscape and significance across 12 major cancer types. Nature 2013; 502: 333-339.
44. Lawrence MS, Stojanov P, Mermel CH, et al., Discovery and saturation analysis of cancer genes across 21 tumour types. Nature 2014; 505: 495-501.
45. Gao J, Aksoy BA, Dogrusoz U, et al., Integrative analysis of complex cancer genomics and clinical profiles using the cBioPortal. Sci Signal 2013; 6: pl1.
46. Turner N, Lambros MB, Horlings HM, et al., Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets. Oncogene 2010; 29: 2013-2023.
47. El-Rifai W, Rutherford S, Knuutila S, et al., Novel DNA copy number losses in chromosome 12q12-q13 in adenoid cystic carcinoma. Neoplasia 2001; 3: 173-178.
48. Turner NC, Reis-Filho JS,. Tackling the diversity of triple-negative breast cancer. Clin Cancer Res 2013; 19: 6380-6388.
49. Gerlinger M, Rowan AJ, Horswell S, et al., Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med 2012; 366: 883-892.
50. de Bruin EC, McGranahan N, Mitter R, et al., Spatial and temporal diversity in genomic instability processes defines lung cancer evolution. Science 2014; 346: 251-256.
51. Alexandrov LB, Nik-Zainal S, Wedge DC, et al., Signatures of mutational processes in human cancer. Nature 2013; 500: 415-421.